Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma.
Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y.
Hayashi H, et al. Among authors: togashi y.
Oncotarget. 2014 May 15;5(9):2588-95. doi: 10.18632/oncotarget.1811.
Oncotarget. 2014.
PMID: 24809949
Free PMC article.